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Sterile attenuation of Plasmodium parasites at the liver-stage either by irradiation or genetic
modiﬁcation, or at the blood-stage by chemoprophylaxis, has been shown to induce
immune responses that can protect against subsequent wild-type infection. However,
following certain interventions, parasite attenuation can be incomplete or non-sterile.
Instead parasites are rendered developmentally stunted but still capable of establishing
an acute infection. In experiments involving Plasmodium berghei ANKA, a model of
experimental cerebral malaria, it has been observed that several forms of attenuated
parasites do not induce cerebral pathology. In this perspective we collect evidence from
studies on murine malaria in particular, and attempt to “connect the dots” between early
immune responses and protection from severe cerebral disease, highlighting potential
parallels to human infection.
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INTRODUCTION
Radiation-attenuated sporozoites, genetically attenuated parasites
and sporozoites administered under chemoprophylaxis have all
been shown to successfully induce long-lasting sterile protection
against malaria infection, in both animal models and humans
(Nussenzweig et al., 1967; Hoffman et al., 2002; Belnoue et al.,
2004; Mueller et al., 2005; Roestenberg et al., 2009; Butler et al.,
2011). Sterile protection is characterized by the elimination of the
parasite through the pre-erythrocytic immune response before it
is able to establish a blood infection, that can be detected micro-
scopically and cause pathology. In contrast, protection from severe
cerebral pathology does not necessitate the complete elimination
of the parasite from the host. Instead, parasites transition from the
liver into the blood but do not cause severe cerebral pathology.
This perspective focusses on attenuated, non-sterile infections,
particularly those from studies on murine malaria, that result
either intentionally or unintentionally from previous interven-
tions such as immunization or genetic manipulation of parasite
lines. Such interventions eventually limit or alleviate the murine
severe disease outcome, experimental cerebral malaria (ECM).
Moreover, we summarize evidence from both published and
unpublished observations that suggest a critical role for early
immune responses in inﬂuencing the development of cerebral
pathology.
Experimental cerebral malaria develops when susceptible
mouse strains are infected with speciﬁc strains of Plasmodium.
For example, infection of C57BL/6 mice with Plasmodium berghei
ANKA (PbA) generates a severe cerebral syndrome generally con-
sidered to be analogous to human cerebral malaria (de Souza
and Riley, 2002). Descriptions of ECM immunopathogenesis are
multifaceted and largely hypothetical, involving an intricate series
of interactions in space and time between both host and pathogen,
but generally start from the onset of blood-stage infection (Renia
et al., 2006). ECM pathology is generally marked by ataxia, ﬁtting,
coma, and eventually death (de Souza and Riley, 2002). Although
subject to some debate (Carvalho, 2010; White et al., 2010; Craig
et al., 2012), the close correlation between mice and humans in
terms of immune responses andneuropathological processes (Hau
andVanHoosier, 2005; de Souza et al., 2010) hasmade ECMa gen-
erally accepted, if sometimes disputed, model (Hunt et al., 2010;
Riley et al., 2010; Langhorne et al., 2011).
Few studies to date have addressed the potential for host
immune responses directed against either the liver-stages or
early blood-stages to modify the immunopathogenesis of ECM.
Our experience is that the apparent absence of ECM follow-
ing parasite manipulation is often considered irrelevant and
hence not fully examined yet, for example during the func-
tional characterization process of a transgenic parasite. Indeed,
the absence of ECM following numerous experimental condi-
tions is an accepted, anecdotally recounted but rarely published
phenomenon.
In an attempt to shed light on a generally disregarded aspect
of murine malaria, we have outlined several examples of malaria
infection that share the same outcome of protection from severe
cerebral complications, but in all probability do not share the
same protective mechanism. It is our hope that highlighting and
cataloging examples of this generally disregarded phenomenon
will both draw attention to the ﬁeld and help piece together
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potential critical factors involved in protection against cerebral
malaria.
INCOMPLETE PARASITE ATTENUATION AT THE LIVER-STAGE
Haussig et al. (2011) recently observed that targeting the api-
coplast by disruption of a Plasmodium-speciﬁc protein that plays
a role in liver merozoite formation (PALM) affected liver-stage
development and the subsequent onset of blood-stage parasitemia.
30% of the palm(-)-immunized mice became patent following a
delay of up to 4days, of which themajority didnot develop cerebral
pathology (Haussig et al., 2011).
Another approach described an experimental vaccination
regime consisting of sporozoite immunization applied concomi-
tantly with either azithromycin or clindamycin drug cover. This
permits full development of the malarial liver-stage, but inhibits
the inheritance and biogenesis of the apicoplast, thus prevent-
ing the onset of blood-stage infection. While sterile protec-
tion was found to depend on IFN-γ producing CD8+ T cells
that exclusively targeted the intra-hepatic stages, it was dose-
dependent and a reduction in the sporozoite numbers used
for immunization led to breakthrough infections. However, all
mice that developed blood-stage infecion featured a delay in
the onset of patency and were apparently protected from ECM
(Friesen et al., 2010).
Further it is known that sterile protection conferred by immu-
nization under chloroquine (CQ) cover relies on a critical thresh-
old of intra-hepatic parasites (Nganou-Makamdop et al., 2012).
Comparable to Friesen et al. we have observed that a reduction in
the sporozoite numbers used for immunization under CQ cover,
does not confer sterile protection against a wild type infection, but
delays the onset of blood-stages and protects against ECM (Pfeil
et al., unpublished).
While the mechanism behind protection against severe cere-
bral symptoms in the models described above still remains
elusive, preliminary data from another experiment suggests a
role for an altered host immune response in the modulation
of ECM outcome. Incomplete attenuation of PbA parasites
achieved via sub-therapeutic administration of a liver acting
anti-malarial substance lead to the suppression of intrahepatic
development, a delay in prepatency and subsequent abroga-
tion of cerebral pathology. This effect was supported by a
robust host immune environment involving a Th1 response and
early T-cell activation in both liver and spleen (Lewis et al.,
unpublished).
A common motif between these observations is develop-
mental impairment or attenuation during the transition from
liver to the intraerythrocytic phase of the malaria parasite.
It is conceivable that this altered transition results in a slow
trickle of parasites into the bloodstream. How exactly this
slow onset of blood-stage parasitemia modulates the immune
response in a way that severe disease is prevented, remains
unknown.
INCOMPLETE PARASITE ATTENUATION AT THE
BLOOD-STAGE
The notion that parasite growth kinetics in the blood can be
linked to cerebral malaria, while tenuous, is not entirely novel.
In fact, several murine studies have documented early growth
defects in the blood that caused an altered disease outcome.
One such example was the oral administration of trioxane
T-10 thioacetals to C57BL/6 mice 24 h after infection with
PbA-infected erythrocytes, which completely abrogated ECM in
treated mice (Jacobine et al., 2012). Deletion of certain non-
essential blood-stage antigens also achieves the same result. For
example P. berghei parasites lacking the endogenous merozoite
surface protein 7 (MSP7) remain viable, but are impaired in
their multiplication rates in the blood (Tewari et al., 2005). A
minor delay in parasite development in vivo, was attributed to
enhanced reticulocyte preference but was sufﬁcient to ablate ECM
in C57BL/6 mice (Tewari et al., 2005; Spaccapelo et al., 2011).
Similar virulence-attenuated phenotypes were also observed in
experiments with parasites lacking plasmepsin 4 (pm4) or
a component of the PTEX, thioredoxin-2 (TRX2) PbTRX-2.
Protection from ECM in the case of pm4 parasites was asso-
ciated with a growth defect in the blood (Spaccapelo et al.,
2010). While PbTRX2 mutants displayed a marked delay in
parasitemia resulting in abrogation of ECM in the majority of
mice, variations in virulence were observed between PbTRX2
clones, which the authors hypothesized resulted from differ-
ences in the number of times the clones had been passaged
(Matthews et al., 2013).
An inference drawn from the examples above suggests that
chemical or genetic methods of attenuation modify parasite
growth in the blood in a way that differs from a natural infection.
This form of attenuation could potentially stall parasite develop-
ment, thereby reducing the burden of viable parasites and the
ensuing immunopathogenesis, thus resulting in the abrogation
of ECM.
PARASITE ATTENUATION AND CLINICAL OUTCOME IN
HUMANS
Although not directly comparable to the examples described
above, similar observations have also been reported from human
clinical trials. The partially protective effect against clinical and
severe disease following immunization of individuals with the
leading malaria vaccine candidate RTS,S represents a good exam-
ple. The fact that a vaccine against pre-erythrocytic stages confers
protection against severe malaria was suggested to stem from
vaccine-induced immune responses that reduced the number
of liver-stage parasites after natural infection. Such partial pre-
erythrocytic immunity may result in the “leakage” of small num-
bers of parasites. This slow onset of blood-stage parasitemiamight
increase the time frame required to establish innate and adaptive
immune responses that inhibit blood-stage growth and conse-
quently limit severe disease (Guinovart et al., 2009). In a similar
setting, long-term reduction in the risk of clinical malaria in Tan-
zanian children was observed following intermittent preventive
treatment with the antimalarial sulfadoxine-pyrimethamine (SP).
It was proposed that the long half-life and possibly anti-liver-stage
acting properties of SP lead to low-dose blood-stage infections
that effectively induce prolonged protection from clinical malaria
(Schellenberg et al., 2001; Greenwood, 2007; Sutherland et al.,
2007). Such clinical studies and many others that test vaccine
efﬁcacy or antimalarial drug potency, however, lack a detailed
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understanding of the dowmstream effects on human cerebral
malaria.
EARLY IMMUNE RESPONSES AND EVENTS THAT MAY
AFFECT DOWNSTREAM IMMUNOPATHOGENESIS
Early immune responses and particularly elements and mecha-
nisms of the innate immune system can inﬂuence downstream
effector responses and consequently disease outcome (O’Garra
and Murphy, 1994; Jankovic et al., 2001; Mitchell et al., 2005).
In vitro observations with P. falciparum and also murine stud-
ies have shown that infected red blood cells and parasite moieties
such as glycosylphosphatidylinositol (GPI) andhemozoin can trig-
ger innate pathways of the immune system, primarily through
toll-like receptor signaling (Schoﬁeld et al., 1996; Coban et al.,
2005). A study in the rodent model, that was published in
2007 identiﬁed TLR-2, -9 and MyD88-dependent signaling as
mediators of ECM (Coban et al., 2007). However, subsequent
studies showed that TLR-deﬁcient mice still succumbed to ECM
(Togbe et al., 2007; Lepenies et al., 2008), thus pointing out
a controversial role for TLRs in the development of cerebral
pathology.
Nevertheless, other components of the innate immune sys-
tem have been implicated in the induction of ECM (Hansen
et al., 2003, 2007; Maglinao et al., 2013; Palomo et al., 2013).
For instance, Hansen et al. (2003) showed that susceptibil-
ity or resistance to ECM was dependent on CD1d-restricted
NKT cells that modulated Th1/Th2 polarization. A subse-
quent study showed that NK cell depletion negated T cell
recruitment to the brains of ECM-affected mice thus sub-
stantiating a role for NK cells in the regulation of adaptive
immune responses that inﬂuence cerebral pathology (Hansen
et al., 2007). Additionally, NK cells and γδ T cells, are also
known as early sources of IFN-γ that could enhance parasite
clearance mechanisms (Seixas and Langhorne, 1999; Artavanis-
Tsakonas and Riley, 2002; Ing and Stevenson, 2009; Inoue et al.,
2013).
Indeed, there is evidence that very early inﬂammatory
responses are capable of altering downstream immunopathogen-
esis in a manner that involves CD8+ T cells and IFN-γ (De Souza
et al., 1997; Mitchell et al., 2005; Lewis et al., unpublished). ECM-
susceptiblemice, co-infected with PbA and PbK173 are completely
protected from ECM and this protection was found to be associ-
ated with increased IFN-γ in the blood at 24 h post-infection
and an increase in transcriptional abundance of IFN-γ, IL-10
and IL-12 in both the liver and spleen (Mitchell et al., 2005).
In this model early production of IFN-γ was attributed pre-
dominantly to CD8+ T cells that are known for their ability to
rapidly produce this cytokine in a non-antigen-speciﬁc manner
thereby contributing to innate immunity, e.g., in the early phase
of bacterial infections (Berg et al., 2002, 2003; Kambayashi et al.,
2003).
This is perhaps contradictory to the received wisdom that ECM
is Th1 in nature and responsibility for pathology lies with IFN-
γ, CD8+ T cells (de Souza and Riley, 2002) and the Th1-biased
C57BL/6mouse (Locksley et al., 1987). The answer partly lies with
the opposing roles of IFN-γ or TNF-α depending on the time of
their production during infection, i.e., early expression correlates
with protection from ECM while later expression promotes ECM
(Grau et al., 1989; de Souza and Riley, 2002; Mitchell et al., 2005).
One could speculate that an early inﬂammatory peak disrupts
the delicate balance required for ECM immunopathogenesis. A
possible explanation is that parasite elimination mechanisms are
enhanced, thus preventing the critical antigen threshold required
for the onset of immunopathogenesis (Howland et al., 2013).
Alternatively, early inﬂammatory responses could also induce
early production of anti-inﬂammatory cytokines such as IL-10,
a critical regulator in ECM immunopathogenesis (Kossodo et al.,
1997; Couper et al., 2008; Niikura et al., 2010). Our preliminary
data also indicates that an early acute systemic inﬂammation may
provoke the production of IL-10 (Lewis et al., unpublished). IL-10
may then alleviate CD8+ T cell activation, proliferation and down-
regulate the expression of adhesion molecules on the vascular
endothelium (Renia et al., 2006). Thus the timing and localization
of the production of pro- and anti-inﬂammatory cytokines is
crucial to the development of cerebral immunopathogenesis.
Although we are limited in our understanding of the impact
of early immune responses on the development of cerebral
malaria in humans, studies from mouse models have sug-
gested that an ability to control the initial parasitemia per-
mits the development of adaptive immune responses that
support an early inﬂammatory response and enhance para-
site clearance (Meding and Langhorne, 1991; Mohan et al.,
1997; van der Heyde et al., 1997; Su and Stevenson, 2000).
An early inﬂammatory response could in turn dampen the
immunopathology that otherwise prevails during a natural infec-
tion.
Since ECM is likely caused by a series of immunopathogenic
mechanisms that are interrelated but not necessarily sequential or
reliant upon each other, the disruption of one mechanism in a
given model may not necessarily translate into the same outcome
in another.
Nevertheless, we propose the following mechanisms by which
growth impairment might play a role in the abrogation of ECM.
A GROWTH DEFECT MAY AFFECT SEQUESTRATION IN PERIPHERAL
ORGANS
Shortly after the onset of blood-stage infection, parasitized ery-
throcytes adhere to the peripheral tissues (Beeson et al., 2001),
inducing the activation of monocytes, neutrophils, and DCs
(Renia et al., 2006). The adherence of parasitized erythrocytes to
the vascular endothelium has been shown to induce chemokine
secretion and provoke an “activated” state in the brain endothe-
lium. Leukocytes and parasitized erythrocytes bound to the
endothelium interfere with the circulation and produce cytotoxic
molecules. This damages the blood-brain-barrier and causes hem-
orrhages and oedema (de Souza et al., 2010). A blood-stage growth
“defect” or “modiﬁcation”may alter the kinetics of the replicating
parasite, thereby altering the localization, severity or timing of par-
asite sequestration. In turn, this may modify the induced innate
immune response.
GROWTH KINETICS COULD ALTER ANTIGEN PRESENTATION
Given the shared antigen repertoire between liver and blood-
stage parasites (Belnoue et al., 2008; Tarun et al., 2008), it is
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conceivable that altered or possibly prolonged presentation of
shared antigens by late liver-stages directly inﬂuences the early
immune response against erythrocytic stages, eventually alter-
ing disease outcome. Additionally, the timing and localization
of parasite sequestration may also impact upon the adaptive
immune response to malaria infection. CD8+ T cells are a crit-
ical requirement for cerebral pathology and disruption of their
chemotaxis to the brain can protect against cerebral pathol-
ogy (Renia et al., 2006). A recent publication indicated that T
cells speciﬁc for a malarial glideosome-associated protein may
be responsible for ECM pathology due to cross-presentation of
parasite antigen by the brain microvessels (Howland et al., 2013).
Activated endothelial cells are capable of presenting antigen in
an MHC-I context (Pober and Cotran, 1991) and are likely to
phagocytose sequestered parasite material for presentation of
antigen to CD8+ T cells (Renia et al., 2006). The authors also
demonstrated that the number of antigen-speciﬁc T cells does
not increase in ECM models or upon the induction of cerebral
pathology. Instead, the degree of cross-presentation of parasite
moieties by the activated brain endothelium is reduced (How-
land et al., 2013). A reduction in parasite sequestration may
therefore reduce the priming of the immune events that would
otherwise, like a line of dominoes, lead to the induction of cerebral
pathology.
PRIMING IN THE SPLEEN COULD BE MODIFIED BY GROWTH
IMPAIRMENT
As the organ responsible for blood ﬁltration, the spleen is
likely to be responsible for the priming and activation of
T cells that subsequently migrate to the brain (Renia et al.,
2006). Indeed, splenectomised mice infected with low doses
of PbK173 do not develop cerebral symptoms (Curfs et al.,
1989; Hermsen et al., 1998). Activation occurs at an early time-
point post-infection and it is conceivable that modiﬁcation of
parasite growth kinetics may reduce the exposure of parasite
moieties to macrophages and dendritic cells within the splenic
tissues, modifying the phagocytosis, processing and presen-
tation of antigen. It is known that CD11chiCD8+ dendritic
cells are responsible for ECM immunopathogenesis (Piva et al.,
2012) by phagocytosing dying cells and processing antigen in
an MHC-I restricted manner (den Haan et al., 2000). Disrupt-
ing this process may modify the priming of lymphocytes which,
in turn, may reduce systemic inﬂammation and endothelial cell
activation.
REGULATORY T CELLS
Although the role of regulatory T cells in malaria is controversial,
it is conceivable that they play a role in the protection we observe
in some models. ECM can be ablated in normal PbA infection
by the expansion of regulatory T cells (Haque et al., 2010). One
possibility is that regulatory T cells temper the pro-inﬂammatory
response (Riley et al., 2006), which is a key factor in the devel-
opment of cerebral malaria. In fact, concomitant infection of
mice with Schistosoma japonicum and P. berghei reduces ECM
mortality by promoting a Th2 response that is supported by pro-
liferating Tregs (Wang et al., 2013). Interestingly, protection from
the severe symptoms of malaria in P. falciparum is also associated
with the expansion of CD4+CD45RO+FOXP3− regulatory T cells
(Walther et al., 2009).
CONCLUSION
The examples elaborated above substantiate a crucial role of
early immune responses in inﬂuencing the immunopatho-
genesis of ECM. While a clear distinction cannot be drawn
between the responses toward late liver-stages and those toward
the early blood-stages, they both seem to exert an effect on
the onset of parasitemia. Attenuated infections could serve
as tools to improve our understanding of the mechanisms
by which early immune responses regulate downstream adap-
tive immunity and consequently cerebral pathology. Elucidat-
ing these mechanisms could help reﬁne future intervention
strategies.
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